Search results for "hydroxymethylglutaryl-CoA reductase inhibitor"

showing 10 items of 185 documents

Short-term atorvastatin treatment does not modify neointimal morphology but reduces MMP-2 expression in normocholesterolemic rabbit stented arteries.

2006

The aim of our study was to explore some potential pleiotropic effects of atorvastatin, after stenting in the iliac arteries of normocholesterolemic rabbits. On day 0, 27 rabbits underwent stent implantation and were randomized into either the control group (standard chow, CTRL, n = 15) or the atorvastatin group (10 mg/kg/d per os, Ator, n = 12). On day 30, the stented arteries were harvested for histomorphometry and neointimal analysis [macrophages, matrix metalloproteinases (MMP-2), tissue inhibitor of metalloproteinase-2, vascular smooth muscle cells, and collagen]. Atorvastatin did not induce significant histomorphometric and inflammatory modifications but reduced neointimal expression …

NeointimaMalemedicine.medical_specialtyStatinVascular smooth musclemedicine.drug_classAtorvastatinHypercholesterolemiaUrologyMatrix metalloproteinaseIliac ArteryMuscle Smooth VascularRestenosisInternal medicinemedicineAtorvastatinAnimalsPyrrolesPharmacologyTissue Inhibitor of Metalloproteinase-2Cellular densityChemistrymedicine.diseaseImmunohistochemistryHeptanoic AcidsCardiologyMatrix Metalloproteinase 2StentsStatin therapyRabbitsHydroxymethylglutaryl-CoA Reductase InhibitorsCardiology and Cardiovascular MedicineTunica Intimamedicine.drugJournal of cardiovascular pharmacology
researchProduct

Nonalcoholic steatohepatitis: the therapeutic challenge of a global epidemic.

2011

Nonalcoholic fatty liver (NAFL) and especially its inflammatory variant nonalcoholic steatohepatitis (NASH) have become a major challenge to healthcare systems worldwide because of the increasing prevalence of its major risk factors obesity and type 2 diabetes, which are closely linked to overeating, physical inactivity, and the metabolic syndrome.Between 10 and 20% of patients with NAFL develop NASH, which can progress to cirrhosis, end-stage liver disease, and hepatocellular carcinoma. The overall mortality in these patients is significantly increased because of both cardiovascular and liver-related complications. Sustained weight loss by diet and exercise, which is the most effective the…

Nonalcoholic steatohepatitisDiet ReducingEndocrinology Diabetes and MetabolismAnti-Inflammatory AgentsType 2 diabetesBioinformaticsBile Acids and SaltsNon-alcoholic Fatty Liver DiseaseGeneticsmedicineAnimalsHumansHypoglycemic AgentsObesityEpidemicsMolecular BiologyRandomized Controlled Trials as TopicNutrition and Dieteticsbusiness.industryFatty liverCell Biologymedicine.diseaseObesityFatty LiverHydroxymethylglutaryl-CoA Reductase InhibitorsCardiology and Cardiovascular MedicinebusinessHealthcare systemCurrent opinion in lipidology
researchProduct

Circulating leukocyte telomere length and oxidative stress: A new target for statin therapy

2011

International audience; Objectives: We investigated the relationship between prior statin therapy and leukocyte telomere length (LTL), as well as their interaction with potential new biomarkers of oxidative deoxyribonucleic acid (DNA) lesions and reactive oxygen species-induced inflammation.Methods and results: From patients admitted for an acute myocardial infarction, LTL was assessed by quantitative polymerase chain reaction (Q-PCR), and leukocyte Finkel-Biskis-Jinkins osteosarcoma (FOS) and 8-oxoguanine DNA glycosylase (OGG1) messenger ribonucleic acid (mRNA) levels were measured by retrotranscription Q-PCR. Patients under prior chronic statin therapy were compared with patients without …

OncologyMaleMyocardial Infarction030204 cardiovascular system & hematologymedicine.disease_causeDNA Glycosylases0302 clinical medicineRisk FactorsLeukocytesMyocardial infarctionComputingMilieux_MISCELLANEOUSAged 80 and over0303 health sciencesReverse Transcriptase Polymerase Chain ReactionConfoundingMiddle AgedTelomere3. Good health[SDV.MHEP.CSC] Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular systemReal-time polymerase chain reactionOsteosarcomaFemalemedicine.symptomCardiology and Cardiovascular MedicineProto-Oncogene Proteins c-fosGenetic Markersmedicine.medical_specialtyStatinmedicine.drug_classInflammationReal-Time Polymerase Chain ReactionRisk Assessment03 medical and health sciences[SDV.MHEP.CSC]Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular systemInternal medicinemedicineHumansRNA MessengerPropensity Score030304 developmental biologyAgedDyslipidemiasChi-Square Distributionbusiness.industrystatinoxidative stress 2medicine.diseaseLeukocyte telomere lengthSurgeryOxidative StressLogistic ModelsinflammationLinear ModelsHydroxymethylglutaryl-CoA Reductase InhibitorsbusinessChi-squared distributionOxidative stress
researchProduct

Statins and angiogenesis in non-cardiovascular diseases.

2022

Statins inhibit HMG-CoA reductase by competitively inhibiting the active site of the enzyme, thus preventing cholesterol synthesis and reducing the risk of developing cardiovascular disease. Many pleiotropic effects of statins have been demonstrated that can be either related or unrelated to their cholesterol-lowering ability. Among these effects are their proangiogenic and antiangiogenic properties that could offer new therapeutic applications. In this regard, pro- and anti-angiogenic properties of statins have been shown to be dose dependent. Statins also appear to have a variety of non-cardiovascular angiogenic effects in many diseases, some examples being ocular disease, brain disease, …

PharmacologyCholesterolNeovascularization PathologicCardiovascular DiseasesNeoplasmsDrug DiscoveryHumansHydroxymethylglutaryl-CoA Reductase InhibitorsAngiogenesis Bone disease Brain disease Cancer Cardiovascular Diabetes Ocular disease Preeclampsia Statins VascularizationDrug discovery today
researchProduct

Statins and new-onset diabetes

2013

Statins are highly efficacious lipid modifying agents that reduce the risk for cardiovascular (CV) events in both primary and secondary prevention settings. However, statins affect molecular mechanisms which adversely impact on insulin sensitivity and β-cell function, thereby increasing risk for new onset diabetes mellitus (NOD). Defining the mechanisms involved is the focus of considerable current investigation. The statins reduce the risk for CV events in normoglycemic patients as well as in those with diabetes mellitus (DM) and their benefits outweigh the risk of inducing NOD. We review the clinical evidence for NOD with statin treatment, as well as the potential mechanisms involved. Our…

PharmacologySecondary preventionLIPID MODIFYING AGENTSbusiness.industrynutritional and metabolic diseasesInsulin sensitivityNodPharmacologyStatin treatmentBioinformaticsmedicine.diseaseRisk AssessmentPrimary PreventionDiabetes Mellitus Type 2New onset diabetesCardiovascular DiseasesDiabetes mellitusDrug DiscoverySecondary PreventionmedicineHumansHydroxymethylglutaryl-CoA Reductase InhibitorsRisk assessmentbusinessnew-onset diabetes mellitus statin cardiovascular events insulin sensitivity primary prevention secondary prevention
researchProduct

Editorial: Ischemic Stroke Prevention

2014

Pharmacologymedicine.medical_specialtySettore MED/09 - Medicina Internabusiness.industryStroke ischemic PreventionBrain IschemiaStrokeInternal medicineIschemic strokemedicineCardiologyAnimalsHumansHydroxymethylglutaryl-CoA Reductase InhibitorsCardiology and Cardiovascular MedicinebusinessPlatelet Aggregation InhibitorsCurrent Vascular Pharmacology
researchProduct

Lipid-lowering nutraceuticals in clinical practice: position paper from an International Lipid Expert Panel

2017

In recent years, there has been growing interest in the possible use of nutraceuticals to improve and optimize dyslipidemia control and therapy. Based on the data from available studies, nutraceuticals might help patients obtain theraputic lipid goals and reduce cardiovascular residual risk. Some nutraceuticals have essential lipid-lowering properties confirmed in studies; some might also have possible positive effects on nonlipid cardiovascular risk factors and have been shown to improve early markers of vascular health such as endothelial function and pulse wave velocity. However, the clinical evidence supporting the use of a single lipid-lowering nutraceutical or a combination of them is…

PhytochemicalsMedicine (miscellaneous)030204 cardiovascular system & hematologyPharmacologyIntestinal absorption0302 clinical medicineRisk FactorsDrug Interactions030212 general & internal medicineRandomized Controlled Trials as TopicNutrition and DieteticsEvidence-Based MedicineOrvostudományok3. Good healthObservational Studies as TopicLiverCardiovascular DiseasesFatty Acids Unsaturatedlipids (amino acids peptides and proteins)nutraceuticalposition papermedicine.medical_specialtyStatinCombination therapymedicine.drug_classKlinikai orvostudományok03 medical and health sciencesMeta-Analysis as TopiclipidmedicineHumansIntensive care medicineLife StyleTriglyceridesDyslipidemiasbusiness.industryProbioticsdyslipidemiaCholesterol HDLEvidence-based medicineCholesterol LDLmedicine.diseaseResidual riskIntestinal AbsorptionrecommendationsDietary SupplementsPosition paperObservational Studies as TopicHydroxymethylglutaryl-CoA Reductase InhibitorsbusinessDyslipidemia
researchProduct

Genetic diagnosis of familial hypercholesterolemia in a South European outbreed population: influence of low-density lipoprotein (LDL) receptor gene …

2001

The aims of this study were to examine the presence of mutations in the low-density lipoprotein receptor gene among subjects clinically diagnosed with familial hypercholesterolemia and to analyze whether the molecular diagnosis helps to predict the response to simvastatin treatment in our familial hypercholesterolemia population. Fifty-five probands and 128 related subjects with familial hypercholesterolemia were studied. Genetic diagnosis was carried out following a three-step protocol based on Southern blot and PCR-single strand conformational polymorphism analysis. A randomized clinical trial with simvastatin was conducted in 42 genetically diagnosed subjects with familial hypercholester…

ProbandAdultMalemedicine.medical_specialtySimvastatinEndocrinology Diabetes and MetabolismClinical BiochemistryPopulationFamilial hypercholesterolemiaBiologyBiochemistryHyperlipoproteinemia Type IIchemistry.chemical_compoundEndocrinologyHigh-density lipoproteinApolipoproteins EInternal medicinemedicineHumanseducationAgedApolipoproteins Beducation.field_of_studyCholesterolBiochemistry (medical)Cholesterol HDLnutritional and metabolic diseasesCholesterol LDLMiddle Agedmedicine.diseaseEndocrinologychemistryReceptors LDLSimvastatinLow-density lipoproteinMutationlipids (amino acids peptides and proteins)FemaleHydroxymethylglutaryl-CoA Reductase InhibitorsLipoproteinmedicine.drugThe Journal of clinical endocrinology and metabolism
researchProduct

Lovastatin attenuates ionizing radiation-induced normal tissue damage in vivo.

2009

Abstract Background and purpose HMG-CoA-reductase inhibitors (statins) are widely used lipid-lowering drugs. Moreover, they have pleiotropic effects on cellular stress responses, proliferation and apoptosis in vitro . Here, we investigated whether lovastatin attenuates acute and subchronic ionizing radiation-induced normal tissue toxicity in vivo . Materials and methods Four hours to 24h after total body irradiation (6Gy) of Balb/c mice, acute pro-inflammatory and pro-fibrotic responses were analyzed. To comprise subchronic radiation toxicity, mice were irradiated twice with 2.5Gy and analyses were performed 3weeks after the first radiation treatment. Molecular markers of inflammation and f…

Programmed cell deathPathologymedicine.medical_specialtyStatinmedicine.drug_classCell SurvivalPharmacologyRadiation DosageMiceRandom AllocationIn vivoFibrosisReference ValuesRadiation IonizingmedicineAnimalsHumansRadiology Nuclear Medicine and imagingLovastatinRNA MessengerRadiation InjuriesLungProbabilityMice Inbred BALB CChemistryTumor Necrosis Factor-alphaNF-kappa BDose-Response Relationship RadiationHematologymedicine.diseaseCTGFIntestinesDisease Models AnimalRadiation Injuries ExperimentalOncologyLiverApoptosisToxicitylipids (amino acids peptides and proteins)FemaleLovastatinHydroxymethylglutaryl-CoA Reductase InhibitorsInflammation Mediatorsmedicine.drugDNA DamageRadiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
researchProduct

Simvastatin Increases the Ability of Roflumilast N-oxide to Inhibit Cigarette Smoke-Induced Epithelial to Mesenchymal Transition in Well-differentiat…

2014

Cigarette smoking contributes to epithelial-mesenchymal transition (EMT) in COPD small bronchi as part of the lung remodeling process. We recently observed that roflumilast N-oxide (RNO), the active metabolite of the PDE4 inhibitor roflumilast, prevents cigarette smoke-induced EMT in differentiated human bronchial epithelial cells. Further, statins were shown to protect renal and alveolar epithelial cells from EMT. To analyze how RNO and simvastatin (SIM) interact on CSE-induced EMT in well-differentiated human bronchial epithelial cells (WD-HBEC) from small bronchi in vitro. Methods: WD-HBEC were stimulated with CSE (2.5%). The mesenchymal markers vimentin, collagen type I and α-SMA, the e…

Pulmonary and Respiratory MedicineCyclopropanesSimvastatinEpithelial-Mesenchymal TransitionAminopyridinesSaludVimentinBronchiPharmacologyMedicineHumansEpithelial–mesenchymal transitionRoflumilastCells Culturedbeta CateninLungbiologybusiness.industryMesenchymal stem cellSmokingEpithelial Cellsrespiratory systemTabaquismoIn vitroBlotTabacomedicine.anatomical_structureSimvastatinBenzamidesbiology.proteinCancer researchPhosphodiesterase 4 InhibitorsHydroxymethylglutaryl-CoA Reductase InhibitorsbusinessReactive Oxygen SpeciesProto-Oncogene Proteins c-aktmedicine.drugCOPD
researchProduct